{"generic":"Omega-3-Acid Ethyl Esters","drugs":["Lovaza","Omega-3-Acid Ethyl Esters","Omtryg"],"mono":{"0":{"id":"928380-s-0","title":"Generic Names","mono":"Omega-3-Acid Ethyl Esters"},"1":{"id":"928380-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928380-s-1-4","title":"Adult Dosing","mono":"<ul><li>evaluate triglyceride levels carefully prior to initiating treatment<\/li><li><b>Hypertriglyceridemia, Adjunct to diet in adults with triglyceride levels 500 mg\/dL or higher:<\/b> Lovaza(R), 4 capsules (4 g) ORALLY once daily OR 2 capsules (2 g) ORALLY twice daily<\/li><li><b>Hypertriglyceridemia, Adjunct to diet in adults with triglyceride levels 500 mg\/dL or higher:<\/b> Omtryg(TM), 4 capsules (4.8 g) ORALLY once daily OR 2 capsules (2.4 g) ORALLY twice daily<\/li><\/ul>"},"1":{"id":"928380-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"928380-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hypertriglyceridemia, Adjunct to diet in adults with triglyceride levels 500 mg\/dL or higher<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Coronary arteriosclerosis - Hypertriglyceridemia<\/li><li>Familial combined hyperlipidemia<\/li><li>Heart failure<\/li><li>Hyperlipidemia - Hypertriglyceridemia, Triglyceride levels less than 500 mg\/dL<\/li><\/ul>"}}},"3":{"id":"928380-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928380-s-3-9","title":"Contraindications","mono":"hypersensitivity (eg, anaphylactic reaction) to omega-3-acid esters or any product component <br\/>"},{"id":"928380-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- symptomatic atrial fibrillation or flutter may recur more often with treatment in patients with paroxysmal or persistent atrial fibrillation, especially during the first 2 to 3 months of therapy<\/li><li>Endocrine:<\/li><li>-- LDL cholesterol increases have been reported; monitoring recommended<\/li><li>Hepatic:<\/li><li>-- ALT or AST elevations may occur; monitoring recommended in patients with hepatic impairment<\/li><li>Immunologic:<\/li><li>-- use caution in patients with known hypersensitivity to fish or shellfish<\/li><\/ul>"},{"id":"928380-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"928380-s-3-12","title":"Breast Feeding","mono":"Micromedex: Milk effects are possible.<br\/>"}]},"5":{"id":"928380-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Burping (4%), Indigestion (3%), Taste sense altered (4%)<br\/><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis<br\/>"},"6":{"id":"928380-s-6","title":"Drug Name Info","sub":{"0":{"id":"928380-s-6-17","title":"US Trade Names","mono":"<ul><li>Lovaza<\/li><li>Omtryg<\/li><\/ul>"},"2":{"id":"928380-s-6-19","title":"Class","mono":"<ul><li>Antihyperlipidemic<\/li><li>Omega-3 Fatty Acid<\/li><\/ul>"},"3":{"id":"928380-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928380-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"928380-s-7","title":"Mechanism Of Action","mono":"Omega-3-acid ethyl esters (Omacor(R)) and Omega-3-acid ethyl esters A (Omtryg(TM)) is a highly purified ethyl ester concentrate of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The mechanism of action is not  entirely understood, however, possible mechanisms of action  include the inhibition of acyl coenzyme A:1,2-diacylglycerol  acyltransferase and increased peroxisomal  beta-oxidation in the liver <br\/>"},"8":{"id":"928380-s-8","title":"Pharmacokinetics","sub":[{"id":"928380-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability, Oral: absorbed as ethyl esters<\/li><li>Effect of Food: Increased exposure<\/li><\/ul>"}]},"9":{"id":"928380-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>administer with or without food<\/li><li>do not puncture gelatin capsules or allow contents to contact foam plastic cups<\/li><li>swallow gelatin capsules whole; do not break open, crush, dissolve, or chew<\/li><\/ul>"},"10":{"id":"928380-s-10","title":"Monitoring","mono":"<ul><li>reduction in triglyceride levels indicates efficacy<\/li><li>LDL-C levels; periodically during therapy<\/li><li>AST and ALT levels; periodically in patients with hepatic impairment<\/li><\/ul>"},"11":{"id":"928380-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Capsule, Liquid Filled: 1 GM<br\/><\/li><li><b>Lovaza<\/b><br\/>Oral Capsule, Liquid Filled: 1 GM<br\/><\/li><\/ul>"},"13":{"id":"928380-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that drug is derived from fish oils. Use caution in patients with fish or shellfish allergies.<\/li><li>Side effects may include eructation, dyspepsia, and taste perversion<\/li><li>Counsel patient on the importance of maintaining a diet and exercise regimen.<\/li><li>Advise patient to swallow capsules whole. Do not break open, crush, dissolve, or chew capsules<\/li><li>Encourage patient to take drug with meals.<\/li><\/ul>"}}}